Business Context and Reporting Period
Lifeward Ltd. (LFWD), an Israel-incorporated company with principal offices in Hudson, MA, filed this Form 8-K on March 17, 2026. The filing addresses a corporate governance issue regarding Nasdaq listing compliance.
Financial Metrics
This filing does not contain financial performance data. There are no reported figures for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The material change reported is the resignation of Hadar Levy from the Board of Directors. This resignation reduced the Audit Committee to two members, causing the Company to fall out of compliance with Nasdaq Listing Rule 5605(c)(2)(A), which mandates a minimum of three audit committee members.
Outlook, Risks, and Contingencies
- Compliance Status: The Company received a notice of non-compliance from Nasdaq but retains its listing status for now. Shares continue to trade under the symbol "LFWD".
- Cure Period: The Company has until the earlier of its next annual meeting of shareholders or February 24, 2027, to regain compliance. If the next annual meeting occurs before August 24, 2026, the deadline is August 24, 2026.
- Risk: Management explicitly states there can be no assurance that the Company will successfully regain compliance within the applicable cure period.
Key Facts for Investor Verification
- Verify the current composition of the Board of Directors and Audit Committee to confirm the vacancy.
- Monitor the Company's progress in appointing a new independent director to restore the three-member Audit Committee requirement.
- Check the scheduled date of the next annual meeting of shareholders to determine the exact compliance deadline.
- Review subsequent filings for any updates on the delisting risk or potential transfer of listing.